Informations sur ce blog - Mes favoris

"Access to Patient-Level Trial Data — A Boon to Drug Developers"

It is ironic that the organizations that most resist wider access to data are the ones that stand to benefit so much from greater transparency.

http://www.nejm.org/doi/full/10.1056/NEJMp1310771

Aucun commentaire:

Enregistrer un commentaire